INTRODUCTION
============

Esophageal leiomyoma is a common type of esophageal tumor. Although the morbidity varies across different studies, it is undoubtedly the most common benign tumor of esophagus, accounting for approximately 70% of esophageal submucosal tumors [@b1-cln_72p197]-[@b4-cln_72p197]. It is considered an irreversible lesion, and it originates from mesenchymal tissue. Most cases occur in adults aged 20 to 80 years, with the average age range of 40 to 50 years [@b1-cln_72p197],[@b5-cln_72p197],[@b6-cln_72p197]. The patients often have diverse symptoms, and the symptoms and their severity level seem to be related to lesion location and shape [@b7-cln_72p197],[@b8-cln_72p197]. Because of the development of endoscopic technology, many non-symptomatic patients with esophageal leiomyomas are diagnosed during normal physical check-ups.

Esophageal leiomyomas always occur in deep layers of the esophagus [@b9-cln_72p197]. Tissue biopsy by forceps may present false-negatives. The conventional endoscopy could produce misdiagnoses because of differences in personal experiences. Endoscopic ultrasonography (EUS) has the ability to check lesions as well as the adjacent organs and structures [@b10-cln_72p197]. It can easily evaluate the depth of lesions, growth directions, metastasis and other useful parameters.

There are many therapies that are currently available to treat with esophageal leiomyomas. Doctors used to perform a thoracotomy to enucleate the whole lesion [@b11-cln_72p197]. By the 1990s, thoracoscopy and laparoscopy were widely applied in this field [@b12-cln_72p197]-[@b14-cln_72p197]. After that, endoscopy and endoscopic operation were developed and widely used. Several treatments have been deployed on esophageal leiomyomas and have achieved good results.

The purpose of this study was to summarize the clinicopathological characteristics of esophageal leiomyoma and to analyze the significance of EUS on the diagnosis and treatment strategy choice of esophageal leiomyomas.

METHODS
=======

Subjects
--------

The patients who were enrolled in this study were those suspected to have an esophageal leiomyoma at the Endoscopy Center of The First Affiliated Hospital, Zhejiang University from January 1^st^, 2009 to May 31^th^, 2015. The total number was 225. The study protocol was approved by the Ethics Committee of The First Affiliated Hospital, Zhejiang University. All patients involved in this study were informed of the potential hazards and signed written informed consent statements.

EUS procedures
--------------

The EUS device was an ultrasound gastroscope (Olympus, EUS2000) with a 12 MHz miniprobe (Olympus, UM-2R). EUS examinations utilized the same preparations as conventional gastroscopy.

The suspected esophageal leiomyoma diagnosis criterion was a homogeneous and hypoechoic structure with clear borders in the ultrasound image and a submucosal lesion in the endoscopic image, with no destruction of the mucosa.

Statistical analysis
--------------------

The parameters that we recorded included the demographic information of each patient, morphological characteristics of the lesions by EUS and CT scan, pathological and immunohistochemical staining features of the specimens, treatments and follow-up conditions. The immunohistochemical staining markers mainly consisted of desmin, CD117, SMA, S100, CD34 and DOG1.

The demographics and clinicopathological parameters were analyzed statistically by IBM SPSS statistics version 19.0 software. Statistical analyses included the Mann-Whitney U test and the χ^2^ test. The statistical significance was defined as *p*\<0.05.

Follow-up
---------

This study was a retrospective study. The follow-up methods included telephone calls and repeated patient visits to the hospital. The follow-up period was calculated from the date that the EUS was implemented.

RESULTS
=======

Characteristics of study subjects
---------------------------------

A total of 225 patients were diagnosed as either having an esophageal leiomyoma or a suspected leiomyoma under EUS. Among them, 182 patients gave pathological specimens from endoscopic treatments, surgery and biopsy. The lesions of 167 patients were confirmed to be consistent with the preoperative diagnosis by pathological examination (91.75%). Fifteen misdiagnosed lesions were actually a mesenchymoma, inflammatory mass, schwannoma or esophageal carcinoma.

The esophageal leiomyoma patients included 100 males (59.9%) and 67 females (40.1%). The mean age of these patients was 50.57±9.983 years (range: 23-72 years), including 51.46±10.434 years for male patients and 49.24±9.339 years for females ([Table 1](#t1-cln_72p197){ref-type="table"}).

The median length of the total hospitalization period was 8±6 d, and the median hospitalization time after treatments was 4±3 d.

Clinicopathological characteristics of esophageal leiomyoma
-----------------------------------------------------------

### Endoscopic characteristics of EUS

Five cases out of the 167 patients had multiple lesions. Four patients had two lesions, and the other one had three.

The lesions of 105 patients originated in the muscularis mucosa (62.9%). Of these, 37.1% infiltrated the muscularis propria (62/167). Of the lesions that infiltrated the muscularis propria, 14.5% infiltrated the superficial muscularis propria, and 85.5%, the non-superficial layer.

In terms of anatomic locations, the median distance to the incisors was 30±12 cm (18-42 cm). The percentages of lesions located in the upper, middle, and lower segments of esophagus were 16.8%, 41.3% and 41.9%, respectively.

In regard to lesion size, the median diameter of all esophageal leiomyomas was 0.72±0.99 cm (0.2-8.5 cm). The diameter of leiomyomas localized in the muscularis mucosa and muscularis propria were 0.52±0.34 cm and 2.07±1.22 cm, respectively.

During EUS observation, 86.8% of the leiomyomas were determined to be homogeneous echo (145/167). The leiomyoma morphologies included spherical (79.6%), fusiform (9.6%), polypoidal (0.6%), and even 10.2% irregular types. Ten patients had lesions that were exophytic type (6.0%).

When comparing the lesions from the muscularis mucosa and muscularis propria, there were no significant difference related to gender (*p*=0.540) or symptoms (*p*=0.949). More irregular- and exophytic-type leiomyomas originated in the muscularis propria than in the muscularis mucosa (*p*\<0.05). More muscularis propria lesions had echoes that were homogeneous (*p*\<0.05).

Whether EUS could accurately diagnose the esophageal leiomyoma was relative to many parameters of the lesion, including shape, growth direction, echo, size, origination and location ([Table 2](#t2-cln_72p197){ref-type="table"}).

### Symptoms

Forty-eight of the 167 patients were diagnosed unexpectedly during medical checkups. Among the 119 patients with symptoms, the most common one was upper abdominal discomfort (40.1%). Approximately 9.0% of the patients suffered from acid reflux and heartburn (15/119). Dysphagia also occurred in 9.0% (15/119) of the patients. Other symptoms included thoracalgia (6.6%), dyspepsia (4.2%), paraesthesia pharynges (1.8%) and nausea (0.6%).

Neither the demographic nor endoscopic characteristics of the leiomyoma had an effect on symptom occurrence; however, specific symptoms, such as dysphagia as a classic symptom, presented statistical correlation with the distance between incisors and lesions.

### Comparison with CT scan

Among esophageal leiomyoma patients, 83 patients were given CT scans for assistance. Twenty-nine patients were reported as having normal esophagi (34.9%). Masses were found in 54 patients, of which 4 patients were diagnosed as having esophageal leiomyomas (4.8%), and 10 patients had ambiguous outcomes (12.0%).

When compared with the EUS observations, esophageal leiomyomas from muscularis propria, with large diameters or inhomogeneous echoes, were easier to detect by CT scan ([Table 3](#t3-cln_72p197){ref-type="table"}).

### Immunohistochemical staining

Only 75 patients agreed to an immunohistochemical examination but not every patient\'s sample displayed all of the biomarkers. SMA and desmin were positive in 97.2% and 94.5% of the samples, respectively, and these were the only markers that were observed in over 90% of the samples. The specific information is detailed in [Table 4](#t4-cln_72p197){ref-type="table"}.

### Treatments

A total of 166 patients were under treatments in our study. Various therapy methods have been used to treat esophageal leiomyomas. With the exception of the 23 patients who received surgical operations (13.8%), the majority of the patients preferred endoscopic treatments. Specifically, most patients chose endoscopic trepanned resection (ETR) (37.7%). Thirty patients received submucosal tunneling endoscopic resection (STER) (18.56%). The numbers of patients who underwent endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD) and endoscopic submucosal excavation (ESE) were 28, 11 and 10, respectively. Electric cauterization was implemented on the remaining one patient.

The intraoperative complications mainly included perforation and intraoperative bleeding (\>50 ml). Perforation occurred in 7 patients (4.2%), and intraoperative bleeding, in 18 patients (10.8%). Among the 143 patients who had endoscopic operations, only two patients endured intraoperative bleeding \>50 ml. The operation methods had no effect on the occurrence of perforation (*p*=1.00). Endoscopic operations led to less intraoperative bleeding than surgical operations (*p*\<0.05) ([Table 5](#t5-cln_72p197){ref-type="table"}).

In comparing leiomyomas from the muscularis mucosa and muscularis propria, there were many differences between these two types of lesions ([Table 6](#t6-cln_72p197){ref-type="table"}). The originating location might significantly impact the therapy choices and prognosis.

Various treatments were used depending on the different originating depths. ESD and EMR were often performed on leiomyomas from the muscularis mucosa. For leiomyomas from the muscularis propria, the main therapies were surgical operations and endoscopic therapies, including ESE and STER. Elderly patients with small, homogeneous, regular type lesions preferred endoscopic therapies more than surgical operations ([Table 7](#t7-cln_72p197){ref-type="table"}).

### Prognosis

The follow-up methods mainly included repeated patient visits to the hospital and telephone calls. A total of 124 patients had subsequent visits after hospital discharge. The follow-up rate was 74.7%. Among these individuals, three had endoscopic ultrasonography, four had CT scans, and the others chose electronic gastroscopy for examination. The mean follow-up time was 26.7±17.6 months.

The postoperative adverse events were divided into short-term and long-term. The short-term postoperative adverse events that we recorded were delayed bleeding, local infection, pneumomediastinum, pneumothorax and pleural effusion. The most common one was pleural effusion, which happened in 28 patients (16.9%). The 23 patients who had surgical operations all suffered from pleural effusion. The incidences of delayed bleeding, local infection, pneumomediastinum, and pneumothorax were 1.2%, 5.4%, 3.6% and 3.0%, respectively. Of 166 patients in our study, 33 had these events. Local infection and pleural effusion occurred more commonly after surgical treatments. In terms of short-term postoperative adverse events, endoscopic treatments might be more advantageous than surgical methods ([Table 8](#t8-cln_72p197){ref-type="table"}).

The long-term adverse events included recurrence, cicatrization, esophageal stenosis, diverticulum and residual lesions. Thirty-six patients formed scar tissue in the esophagus (21.7%). Three patients had residual lesions. Only one patient developed esophageal diverticulum. There was no significant difference between endoscopic and surgical treatments in terms of long-term adverse effects. Lesions originating from the muscularis propria exhibited the same long-term effects after ESE or STER as with surgical treatments.

DISCUSSION
==========

With the use of EUS, our study reveals the peak incidence age of esophageal leiomyoma is approximately 40-60 years. Male patients are slightly more likely to develop these lesions than females [@b1-cln_72p197],[@b15-cln_72p197]. It has been established that 83.2% of these lesions are located in the middle, lower segment of the esophagus, and the percentage of symptomatic individuals is 71.3%. Dysphagia occurs more frequently in patients with lower lesions. Furthermore, none of the symptoms have any correlation with lesion location. Compared with previous studies, the percentage of symptomatic individuals is obviously higher [@b7-cln_72p197],[@b16-cln_72p197]. This result may be because of an admission bias, the rising attention to self-health, nerve sensitivity and mental fluctuation.

In the past, conventional endoscopy and CT scans were often used to detect esophageal lesions. More than half of the lesions grow from the muscularis mucosa. Conventional endoscopy can easily detect superficial lesions, but it cannot evaluate origination, growth direction and some other characteristics. In addition, approximately 40% of esophageal leiomyomas originate from the muscularis propria, which may increase the difficulty of diagnosis and biopsy. All these situations make it very hard to differentiate esophageal leiomyomas from other analogous lesions.

In our research, CT scans are good at discovering large, irregular leiomyomas with deep origination. Depending on its sharpness, it may not be easy to clearly identify the nature of the lesions.

EUS has significant advantages over these two methods. It can discover lesions, and assess depth, size, shape, and growth direction. Finally, it can distinguish the nature of lesions. It can significantly impact the diagnosis and selection of the treatment strategy. EUS had good sensitivity in our study. Some esophageal leiomyomas with specific characteristics are diagnosed more easily, including the endophytic type, inhomogeneous echo, and superficial origination. Although this may be related to the doctor\'s experience, it also reflects the endoscopic characteristics. Based on this information, combining conventional endoscopy and CT scan for screening, followed by EUS could allow for lesions to be observed more precisely.

Esophageal leiomyomas from the muscularis mucosa tend to have a better prognosis than the ones from the muscularis propria. After endoscopic treatment, the patients with superficial lesions can resume their diets and leave the hospital earlier. They suffer less postoperation adverse events. The possible reasons for this difference may include smaller sizes, more regular shapes, and growth toward the lumen.

Currently, most patients choose endoscopic therapy to treat superficial esophageal leiomyomas. When compared with surgical operation, it reduces the chance of intraoperative hemorrhage and short-term adverse events after treatments. It appears to be much safer. In terms of leiomyomas from the muscularis propria, there are also some good endoscopic methods that can be used, such as ESE and STER [@b17-cln_72p197]. They can achieve similar curative effects and prognosis as surgical treatments. EUS is not only good for diagnosing esophageal leiomyoma but also for contributing to treatment strategy choice.

On the other hand, EUS cannot completely avoid misdiagnoses, especially for some tumors in mesenchymal tissue. In our study, misdiagnosed lesions may contain mesenchymomas and schwannomas. Combining EUS with other examinations may be a good method to solve this problem. It will be a effective way, if the diagnoses combined with histopathology. These three lesions share some commonalities when observed during EUS and have similarities in microscopic morphology. The definite diagnosis is assisted by immunohistochemical staining. Leiomyomas are usually positive for desmin, SMA, CD117, CD34 and DOG-1 at low levels. Schwannomas have typical S100 positivity. Mesenchymomas are positive for CD117, CD34 and DOG-1 at a high level. Several types of biopsies can be implemented by EUS. Microscopic examinations and immunohistochemical staining have the ability to distinguish the nature of lesions.

In conclusion, our research reveals the recent clinicopathologic developments of esophageal leiomyoma. EUS exhibits high accuracy in esophageal leiomyoma diagnosis and provides great support in selecting treatments.
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###### 

Patients' basic characteristics.

  ------------------------------------------------------------- ---------------------
  Age (years) \[mean±SD (range)\]                               50.57±9.983 (23-72)
  Male (N)                                                      100
  Female (N)                                                    67
  Length of total hospitalization period (days) \[median±QR\]   8±6
  Hospitalization time after treatments (days) \[median±QR\]    4±3
  muscularis mucosa (N)                                         105
  muscularis propria (N)                                        62
  Distance to incisors (cm) \[median±QR (range)\]               30±12 (18-42)
  Location                                                      
  Upper (N)                                                     28
  Middle (N)                                                    69
  Lower (N)                                                     70
  Diameter \[median±QR (range)\]                                0.72±0.99 (0.2-8.5)
  ------------------------------------------------------------- ---------------------

###### 

EUS characteristics of confirmed and suspected leiomyomas.

                                                  EUS confirmed   EUS suspected   *p* value
  --------------------------- ------------------- --------------- --------------- ----------------
  shape (N)                   irregular type      11              6               *p*\<0.05
  other types                 144                 6                               
  growth direction (N)        endophytic type     148             9               *p*=0.02\<0.05
  exophytic type              7                   3                               
  echo (N)                    homogeneous         143             2               *p*\<0.05
  heterogeneous               12                  10                              
  origination (N)             muscularis mucosa   105             0               *p*\<0.05
  muscularis propria          50                  12                              
  distance to incisors (cm)   29±11               39±9            *p*\<0.05       
  lesion diameter (cm)        0.65±0.74           3.40±2.18       *p*\<0.05       

###### 

EUS characteristics of leiomyomas in comparison with CT scans.

                           CT missing   CT discovery   *p* value
  ------------------------ ------------ -------------- ----------------
  diameter (cm)            0.56±0.58    1.87±2.29      *p*\<0.05
  muscularis mucosa (N)    19           20             *p*=0.01\<0.05
  muscularis propria (N)   10           34             
  irregular type (N)       27           39             *p*=0.03\<0.05
  other types (N)          2            15             
  endophytic type (N)      28           45             *p*=0.16
  exophytic type (N)       1            9              

###### 

Immunohistochemical staining of the leiomyomas.

           Positive   N    Percentage (%)
  -------- ---------- ---- ----------------
  Desmin   69         73   94.5
  CD117    20         74   27.0
  SMA      70         72   97.2
  S100     1          66   1.5
  CD34     27         70   38.6
  DOG1     4          43   9.3

###### 

Intraoperative complications of endoscopic operations.

  Complication                  endoscopic operation   surgical operation   *P* value   
  ----------------------------- ---------------------- -------------------- ----------- -----------
  perforation (N)               Y                      6                    1           *p*=1.00
  N                             137                    22                               
  intraoperative bleeding (N)   Y                      2                    16          *p*\<0.05
  N                             141                    7                                

###### 

Characteristics of esophageal leiomyomas from the muscularis mucosa and muscularis propria.

                                                muscularis mucosa   muscularis propria   *p* value
  --------------------------------------------- ------------------- -------------------- ----------------
  no symptoms (N)                               75                  44                   *p*=0.95
  age                                           51.90±9.38          48.31±10.64          *p*=0.02\<0.05
  distance to incisors (cm)                     27.00±10.00         35.50±11.00          *p*\<0.05
  lesion diameter (cm)                          0.52±0.34           1.87±1.58            *p*\<0.05
  irregular type (N)                            0                   17                   *p*\<0.05
  exophytic growth (N)                          1                   9                    *p*\<0.05
  homogeneous echo (N)                          2                   20                   *p*\<0.05
  EUS confirmed (N)                             105                 50                   *p*\<0.05
  intraoperative bleeding\>50 ml (N)            1                   17                   *p*\<0.05
  intraoperative perforation (N)                0                   7                    *p*\<0.05
  hospitalization time after treatment (days)   3±2                 6±2                  *p*\<0.05
  open diet time (days)                         1±1                 4±3                  *p*\<0.05

###### 

Characteristics of patients who underwent ESE+STER and surgical operation.

                              ESE+STER      surgical operation   *p* value
  --------------------------- ------------- -------------------- ------------------
  male                        25            14                   *p*=0.93
  female                      15            8                    
  age                         50.30±10.50   44.68±10.13          *p*=0.046\<0.050
  symptom                     31            13                   *p*=0.13
  no symptom                  9             9                    
  EUS confirmed               35            15                   *p*=0.13
  EUS suspected               5             7                    
  irregular type              35            10                   *p*\<0.05
  other types                 5             12                   
  endophytic growth           37            16                   *p*=0.08
  exophytic growth            3             6                    
  homogeneous echo            33            9                    *p*\<0.050
  inhomogeneous echo          7             17                   
  distance to incisors (cm)   36.00±11.00   35.00±11.25          *p*=0.70
  lesion diameter (cm)        1.28±0.96     2.69±1.73            *p*\<0.05

###### 

Postoperative adverse events of endoscopic and surgical operation.

  postoperative adverse events   endoscopic operation   surgical operation   *p* value   
  ------------------------------ ---------------------- -------------------- ----------- -----------
  delayed bleeding (N)           Y                      1                    1           *p*=0.259
  N                              142                    22                               
  local infection (N)            Y                      3                    6           *p*\<0.05
  N                              140                    17                               
  pneumomediastinum (N)          Y                      6                    0           *p*=0.597
  N                              137                    23                               
  pneumothorax (N)               Y                      3                    2           *p*=0.142
  N                              140                    21                               
  pleural effusion (N)           Y                      5                    23          *p*\<0.05
  N                              138                    0                                
  short-term adverse events      Y                      10                   23          *p*\<0.05
  N                              133                    0                                
